Brief: Imunon Announces Translational Data From Phase 1/2 Ovation 2 Study Of Imnn-001 In Advanced Ovarian Cancer

Imunon

19/02/2025 15:22

Feb 19 (Reuters) - Imunon Inc  IMNN.O :
    * IMUNON ANNOUNCES TRANSLATIONAL DATA FROM PHASE 1/2 OVATION
2
STUDY OF IMNN-001 IN ADVANCED OVARIAN CANCER
    * IMUNON INC - IMNN-001 SHOWS FAVORABLE SAFETY PROFILE WITH
NO
SERIOUS ADVERSE EVENTS
    * IMUNON INC - TO INITIATE PHASE 3 TRIAL OF IMNN-001 IN Q1
2025

Source text:  ID:nGNXrlPq5 
Further company coverage:  IMNN.O 

 ((Reuters.Briefs@thomsonreuters.com;))